Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03143270 · ClinicalTrials.gov registry record · Early Phase 1

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

A Early Phase 1 study of Liver Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Early Phase 1
Development phase
20
Enrollment target
9
Study locations

NCT03143270 is a Early Phase 1 study of Liver Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 9 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03143270, a Early Phase 1 study of Liver Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
9
Study locations

Study Summary

The purpose of the study is to find out the effects of using nivolumab with Drug Eluting Bead Transarterial Chemoembolization (deb-TACE) in the treatment of liver cancer.

Conditions Studied

Liver Cancer

Interventions

  • DRUG Nivolumab
  • DRUG Drug Eluting Bead Transarterial Chemoembolization

Study Locations (9)

New York

  • Memorial Sloan Kettering Cancer Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering at Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Missouri

  • Washington University School of Medicine - St Louis

Pennsylvania

  • Abramson Cancer Center at University of Pennsylvania Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-04-28
Est. Completion 2026-04
Phase Early Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03143270

The ClinicalTrials.gov registry entry for NCT03143270 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT03143270 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Missouri.

Frequently Asked Questions

What is clinical trial NCT03143270 about?

NCT03143270 is a clinical study titled "A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer". The purpose of the study is to find out the effects of using nivolumab with Drug Eluting Bead Transarterial Chemoembolization (deb-TACE) in the treatment of liver cancer.

What is the current status of trial NCT03143270?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-04-28. Estimated completion is 2026-04.

What conditions does trial NCT03143270 study?

This clinical trial studies the following conditions: Liver Cancer.

What interventions are being tested in trial NCT03143270?

The interventions under investigation include: Nivolumab (DRUG), Drug Eluting Bead Transarterial Chemoembolization (DRUG).

Who is sponsoring clinical trial NCT03143270?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03143270 being conducted?

This trial has 9 study locations across Missouri, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Cancer

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.